Glioblastoma is the most common subtype of primary brain tumors in adults. These tumors are highly invasive. Median survival after diagnosis is approximately 12 months. Chemotherapy with nitrosourea, methylating agents such as procarbazine or temozolomide, or other agents is effective and can prolong survival. However, a significant obstacle to the treatment has been the hematopoietic toxicity of chemo- therapeutic agents like 1,3-bis(2-chloroethyl)-1 -nitrosourea (BCNU) and temozolomide, which has limited the ability to dose-escalate the drugs. This hematopoietic toxicity is even more pronounced when BCNU or temozolomide are combined with O6-benzylguanine (O6-BG), an agent which inhibits O6-alkylguanine DNA alkyltransferase, a major resistance mechanism in gliomas. We have recently demonstrated in a clinically relevant large animal model that genetic modification of hematopoietic stem cells with the P140K mutant of methylguanine methyltransferase (MGMT) results in chemoprotection and the ability to administer higher doses of temozolomide and BCNU when given in combination with O6-BG. Based on these findings we hypothesize that chemoprotection with MGMT (P140K) will allow the administration of higher doses of temozolomide and thus potentially improve the efficacy of this drug in the treatment of patients with high-grade gliomas. Since efficient engraftment of gene-modified cells is important for the success of this strategy, we propose a 2-part approach. In the first part, we propose a dose-escalation of temozolomide with a fixed dose of BCNU to enhance engraftment of gene-modified chemoprotected peripheral blood stem cells, followed by fixed doses of temozolomide with O6-BG. The initial dose of BCNU and temozolomide will be based on the maximum tolerated dose (MTD) published by the North American Brain Tumor Consortium. This approach will allow us to maximize engraftment of chemoprotected cells and thus also maximize the ability to dose-escalate temozolomide. The initial dose of temozolomide will be based on the published MTD for this combination. In the second part of the study, we will use the MTD of BCNU and temozolomide with support of chemoprotected peripheral blood stem cells and perform a dose-escalation of temozolomide with O6-BG. Thus, this study will address the safety, feasibility, and tumor response of dose-intensive chemotherapy in combination with chemoprotected autologous stem cells in patients with glioblastomas. In addition, we will perform a comprehensive molecular analysis of the gene-modified cells which will provide highly relevant information for stem cell gene therapy studies. Research proposed in this study could, therefore, significantly improve the treatment and survival of patients with glioblastoma and also provide important safety and feasibility information for stem cell gene therapy applications for other diseases such as genetic disorders and AIDS. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA114218-01A2
Application #
7150854
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Wu, Roy S
Project Start
2006-08-16
Project End
2011-07-31
Budget Start
2006-08-16
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$461,965
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cornetta, Kenneth; Duffy, Lisa; Feldman, Steven A et al. (2018) Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Mol Ther Methods Clin Dev 10:371-378
Adair, Jennifer E; Johnston, Sandra K; Mrugala, Maciej M et al. (2014) Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest 124:4082-92
Beard, Brian C; Adair, Jennifer E; Trobridge, Grant D et al. (2014) High-throughput genomic mapping of vector integration sites in gene therapy studies. Methods Mol Biol 1185:321-44
Matrajt, Laura; Younan, Patrick M; Kiem, Hans-Peter et al. (2014) The majority of CD4+ T-cell depletion during acute simian-human immunodeficiency virus SHIV89.6P infection occurs in uninfected cells. J Virol 88:3202-12
Mrugala, Maciej M; Adair, Jennifer E; Kiem, Hans-Peter (2012) Outside the box--novel therapeutic strategies for glioblastoma. Cancer J 18:51-8
Adair, Jennifer E; Beard, Brian C; Trobridge, Grant D et al. (2012) Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 4:133ra57
Mrugala, Maciej M; Adair, Jennifer; Kiem, Hans-Peter (2012) Chemoprotection in glioblastoma therapy: reality or a dream? CNS Oncol 1:11-4
Watts, Korashon Lynn; Adair, Jennifer; Kiem, Hans-Peter (2011) Hematopoietic stem cell expansion and gene therapy. Cytotherapy 13:1164-71
Mrugala, M M; Adair, J; Kiem, H-P (2010) Temozolomide: Expanding its role in brain cancer. Drugs Today (Barc) 46:833-46
Wohlfahrt, Martin E; Beard, Brian C; Lieber, Andre et al. (2007) A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 67:8783-90